KRAS and neoplasm: Similarly, a retrospective pooled analysis of the two pivotal cetuximab studies demonstrated that the best treatment outcomes were observed in patients with both KRAS wild-type and BRAF wild-type tumours, but there were too few patients with BRAF mutations to determine whether BRAF mutation status alone could predict response to therapy [167].